Trial IRCT20151227025726N20
Publication Tabarsi P, Int Immunopharmacol (2020) (published paper)
Funding: Public/non profit (Shahid Beheshti University of Medical Sciences)
Conflict of interest: No
Methods | |
RCT Blinding: Unblinded | |
Location :
Single center / Iran Follow-up duration (days): 28 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
IV Ig 400 mg/kg IV once a day for 3 days |
|
Control
Standard care | |
Participants | |
Randomized participants : Standard care=32 IV Ig=52 | |
Characteristics of participants N= 84 Mean age : NR 65 males Severity : Mild: n=0 / Moderate: n=0 / Severe: n=84 Critical: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Need for mechanical ventilation, need of admission to critical care unit, and death. | |
In the report Need for invasive mechanical ventilation and oxygenation, the need for admission to the Intensive Care Unit (ICU), and the mortality rate. | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Not reported |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment | In addition to the published article, the study registry was used in data extraction and risk of bias assessment. The study protocol and statistical analysis plan were not available at time of extraction. The target sample size specified in the registry was achieved. Some outcomes that were reported (e.g., length of hospital stay, length of ICU stay, lab values) were not pre-specified in the registry. There is no change from the trial registration in the intervention and control treatments. All participants in the intervention group only were pre-medicated with hydrocortisone, paracetamol, and antihistamine 30 minutes before the IV Ig injection. |